Multi-center Clinical Observation of FCVB in Guangdong Province

Sponsor
Sun Yat-sen University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03908515
Collaborator
(none)
100
1
13
7.7

Study Details

Study Description

Brief Summary

This study provides further theoretical guidance for clinical application of FCVB through observing and collecting various indicators before and after surgical treatment of the FCVB in the real world.

Condition or Disease Intervention/Treatment Phase
  • Device: Foldable Capsular Vitreous Body (FCVB)

Detailed Description

  1. Research purpose: Collect and analyze the medical data in clinical work, in order to provide further theoretical guidance for the clinical application of FCVB.

  2. Inclusion criteria: 1) Patients with severe retinal detachment, cannot be cured with existing vitreous substitutes, and are scheduled for FCVB implantation surgery; 2) Patients with silicone oil dependent eye, silicone oil emulsification, and chooses FCVB surgery; 3) Patients whose eyeball Atrophy, and strongly demand eye protection.

  3. Exclusion criteria: 1) Patients with positive urine pregnancy test; 2) Patients with FCVB removed and switched to other alternative treatments; 3) Patients the investigator consider are not suitable for this clinical trial.

  4. Endpoint Primary endpoint: Changes in corneal transverse diameter and ocular protrusion after 1 year of FCVB implantation.

Secondary endpoints: visual acuity and intraocular pressure; local inflammatory response and complications evaluation; satisfaction investigated by questionnaire survey.

  1. Process Before surgery, collecting the patient's medical history and pre-operative related specialist examination data and subjective opinions of doctors on surgical indications. Recording the surgical procedure, intraoperative complications. After surgery (3 days, 1 week, 2 weeks, 4 weeks, 3 months, 6 months after surgery, 1 year and 1 year follow-up every year), using visual acuity chart, slit lamp microscope, ophthalmoscope, intraocular pressure, Hertel exophthalmometer, vernier caliper to observe the patient's visual acuity, local inflammatory reaction, intraocular pressure and eyeball atrophy changes.

  2. Efficacy evaluation Main indicators: the changes of corneal transverse diameter and ocular protrusion were observed 1 year after FCVB implantation.

Secondary indicators: visual acuity and intraocular pressure; local inflammatory response and complications evaluation; satisfaction investigated through questionnaire survey.

  1. Safety evaluation Adverse events that occurred during all studies.

  2. Termination criteria During the clinical trial, the clinical trial shall be terminated in any of the following cases; (1) FCVB cannot be implanted (2) Subjects who fail to comply with the program requirements (including loss of follow-up) are subject to termination by the study physician; (3) a female patient who is intentionally pregnant or a female subject who has been confirmed to have been pregnant; (4) Participated in other clinical trials after participating in this clinical trial; (5) Adverse events or serious adverse events occurred during the trial and were unable to continue participating in the study; (6) The subject withdraws the informed consent or requests termination of the trial for some objective reason.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Multi-center Clinical Observation of FCVB in Guangdong Province
Anticipated Study Start Date :
May 1, 2019
Anticipated Primary Completion Date :
May 31, 2019
Anticipated Study Completion Date :
May 31, 2020

Outcome Measures

Primary Outcome Measures

  1. Corneal transverse diameter change [Corneal transverse diameter change from 1day before surgery to 1 year after surgery]

    Determine the degree of eyeball atrophy through the change of transverse Diameter of the cornea

  2. Ocular protrusion change [Ocular protrusion change from 1day before surgery to 1 year after surgery]

    Determine the degree of eyeball atrophy through the ocular protrusion change

Secondary Outcome Measures

  1. Visual acuity [3 days, 1 week, 2 weeks, 4 weeks, 3 months, 6 months after surgery, 1 year after surgery]

    Postoperative visual acuity

  2. Intraocular pressure [3 days, 1 week, 2 weeks, 4 weeks, 3 months, 6 months after surgery, 1 year after surgery]

    Postoperative intraocular pressure

  3. Local inflammatory response [3 days, 1 week, 2 weeks, 4 weeks, 3 months, 6 months after surgery, 1 year after surgery]

    Evaluation of postoperative complications

  4. Patients satisfaction [3 days, 1 week, 2 weeks, 4 weeks, 3 months, 6 months after surgery, 1 year after surgery]

    Postoperative patients satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with the diagnose that severe retinal detachment and cannot be cured with existing vitreous substitutes, or silicone oil dependent eye accompanied with silicone oil emulsification, or eyeball atrophy meanwhile patients strongly demand keeping eyeball.

  2. Patients agree to receive FCVB implantation surgery.

Exclusion Criteria:
  1. Patients whose urine pregnancy test are positive.

  2. Patients whose FCVB have been removed and switched to other alternative treatments.

  3. Patients whom the investigator consider are not suitable for this clinical trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic Center of Sun yat-sen Universtiy Guangzhou Guangdong China 510000

Sponsors and Collaborators

  • Sun Yat-sen University

Investigators

  • Study Chair: Xiaofeng Lin, PhD, Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xiaofeng Lin, associate dean of Zhongshan Ophthalmic Center, Sun Yat-sen University, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT03908515
Other Study ID Numbers:
  • FCVB 2019
First Posted:
Apr 9, 2019
Last Update Posted:
Apr 16, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xiaofeng Lin, associate dean of Zhongshan Ophthalmic Center, Sun Yat-sen University, Sun Yat-sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 16, 2019